Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 80 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents  
EDITORIAL
Year : 2017  |  Volume : 7  |  Issue : 3  |  Page : 149  

Insulin resistance: Quest for surrogate markers


Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Date of Web Publication14-Aug-2017

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 101, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijabmr.IJABMR_198_17

Rights and Permissions

How to cite this article:
Mahajan R. Insulin resistance: Quest for surrogate markers. Int J App Basic Med Res 2017;7:149

How to cite this URL:
Mahajan R. Insulin resistance: Quest for surrogate markers. Int J App Basic Med Res [serial online] 2017 [cited 2017 Oct 19];7:149. Available from: http://www.ijabmr.org/text.asp?2017/7/3/149/212955



Insulin resistance (IR) is defined as a decreased response of the peripheral tissues to insulin action. IR results from the inability of insulin to act normally in regulating nutrient metabolism in peripheral tissues. Individuals with IR are prone to develop type 2 diabetes mellitus. IR has been recognized as the integral feature of the so-called metabolic syndrome, which includes glucose intolerance, IR, obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and accelerated atherosclerosis.[1]

The presentation of IR depends on the type and stage of the resistance. Many patients do not develop overt diabetes despite extreme IR. Other patients present with cases of severe hyperglycemia that require large quantities of insulin and may present with the classic symptoms of diabetes mellitus, such as polyuria, polydipsia, polyphagia, and weight loss. Others may present as metabolic syndrome, obesity, history of hypertension, coronary artery disease, etc.[2]

IR is an established independent predictor of a range of disorders. As resistance to insulin sets in long before any disease signs start appearing, so it is important to categorize and treat individuals with IR as early as possible.[3] Moreover, IR affects a wide array of disease, so medical science is always on the lookout for sensitive and specific surrogate markers for IR so as to have early detection and treatment. Besides markers serve as sensitive detectors of early target organ damage.[4]

Various methods employed to measure IR include – hyperinsulinemic-euglycemic glucose clamp, oral glucose tolerance test, measurement of fasting insulin levels, glucose/insulin ratio, insulinogenic index, homeostasis model assessment, quantitative insulin sensitivity check index, etc.[5] However, most of these methods are difficult to apply in clinical practice for various reasons – require repeated blood sampling, require measurement of insulin levels, and analytical methods for measuring insulin levels are not standardized across all laboratories;[6] there is need to have secondary derived surrogate markers for IR.

Various derived markers in use for IR are – Matsuda index, Gutt index, Stumvoll index, and Avignon index; all applying mathematical equations.[5] Some newly marked markers for IR, mostly products/substrate of inflammation are – insulin growth factor binding protein-1, C-reactive protein, ferritin, adiponectin, and tumor necrosis factor-alpha, etc.

However, the buck does not stop here. Recently, the relationship of leptin and adrenomedullin has been studied as markers of IR particularly in polycystic ovary disease patients, and a positive association has been found.[7],[8] These two may prove to be markers of the future for IR and may augment the already enriched kitty of markers for IR.



 
   References Top

1.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.  Back to cited text no. 1
    
2.
Olatunbosun ST, Talavera F, Schalch DS, Griffing GT, Schade DS. Insulin Resistance Clinical Presentation. Medscape; 2015. Available from: http://www.emedicine.medscape.com/article/122501-clinical. [Last cited on 2017 Jun 05].  Back to cited text no. 2
    
3.
Rao G. Insulin resistance syndrome. Am Fam Physician 2001;63:1159-63, 1165-6.  Back to cited text no. 3
    
4.
Dzau VJ. Markers of malign across the cardiovascular continuum: Interpretation and application. Circulation 2004;109 25 Suppl 1:IV1-2.  Back to cited text no. 4
    
5.
Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 2010;1:36-47.  Back to cited text no. 5
    
6.
Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes 1996;45:242-56.  Back to cited text no. 6
    
7.
Nasrat H, Patra SK, Goswami B, Jain A, Raghunandan C. Study of association of leptin and insulin resistance markers in patients of PCOS. Indian J Clin Biochem 2016;31:104-7.  Back to cited text no. 7
    
8.
Sahin I, Celik O, Celik N, Keskin L, Dogru A, Dogru I, et al. Adrenomedullin: Possible predictor of insulin resistance in women with polycystic ovary syndrome. J Endocrinol Invest 2012;35:553-6.  Back to cited text no. 8
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed348    
    Printed12    
    Emailed0    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal